Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
We performed a cost-effectiveness simulation of acipimox, bezafibrate, fenofibrate and gemfibrozil in patients with hyperlipoproteinaemia type IIb and IV (Frederickson).  A distinction was made between patients with HLP type IIb and IV and HLP associated with diabetes mellitus type II (NIDDM).  Direct costs were assessed as those incurred by social security for the treatment, and indirect costs were not taken into account.  In appropriate dosages, all 4 substances can be considered equally efficacious in lowering lipid levels, although gallstones occur 3 times more frequently in patients treated with fibrates than in those treated with acipimox.  Acquisition costs of the 4 drugs under consideration are comparable.  Thus, when hospitalisation costs for treatment of gallstones are taken into account, therapy with acipimox is more cost effective than fibrate therapy.
Institute for Medical Informatics and Biostatistics, Bachtelenweg, Riehen, Switzerland.
R
R
Bergemann
A
A
Brandt
W
W
Siegrist
D001629:Bezafibrate / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D011345:Fenofibrate / Q000191:economics / Q000627:therapeutic use; D015248:Gemfibrozil / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000453:epidemiology; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy* / Q000453:epidemiology; D017059:Models, Econometric; D011719:Pyrazines / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome